Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KWAR23, an anti-human SIRPα antibody, exhibits high-affinity binding to human SIRPα, inhibiting its interaction with CD47. Demonstrating antitumor activity, KWAR23 is efficacious in conjunction with tumor-opsonizing antibodies, making it a valuable agent for cancer immunotherapy research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | KWAR23, an anti-human SIRPα antibody, exhibits high-affinity binding to human SIRPα, inhibiting its interaction with CD47. Demonstrating antitumor activity, KWAR23 is efficacious in conjunction with tumor-opsonizing antibodies, making it a valuable agent for cancer immunotherapy research [1]. |
In vitro | KWAR 23, at concentrations ranging from 0 to 1 μM over a 4-hour exposure, demonstrates antitumor properties by activating human neutrophils and macrophages [1]. Furthermore, it stimulates macrophage-mediated phagocytosis within cell lines derived from human tumors [1]. |
In vivo | KWAR23, administered via intraperitoneal injection at a dosage of 10 mg/kg biannually for 21 days, demonstrates potent antitumor effects in a human SIRPA knockin mouse model [1]. Additionally, it bolsters the antitumor responses of neutrophils and macrophages in SRG mice [1]. |
Molecular Weight | N/A |
CAS No. | 2243227-60-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KWAR 23 2243227-60-1 inhibitor inhibit